Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Global X Cybersecurity (BUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Global X Cybersecurity — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $288 (market cap $39.89B), while Global X Cybersecurity trades at $39.72. The key difference: Global X Cybersecurity is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | BUG | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Sector/Thematic |
52-Week High | $491.22 | $40.85 |
52-Week Low | $278.09 | $23.30 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
BUG trades at $39.37, down 3.62% today, but maintains a bullish technical outlook with strong moving average signals. The cybersecurity ETF benefits from growing industry spending exceeding $300 billion in 2026, driven by AI-powered threats and corporate security budgets. However, key oscillators show neutral sentiment with RSI readings above 80 indicating potential overbought conditions.
The ETF faces valuation concerns with premium PEG ratios among top holdings, though cybersecurity remains a defensive growth theme. Risks include AI disruption to security models and competitive ETF pressure. Support at $38 and resistance at $41-43 define near-term trading ranges amid mixed technical signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Global X Cybersecurity
BUG is a thematic ETF that invests in companies at the forefront of the global cybersecurity industry. It provides concentrated exposure to leaders in network security, endpoint protection, and cloud security, such as Fortinet, Akamai, and CrowdStrike.
Read more on BUG →
